Anthony Philippakis
Venture Partner @ Google Ventures
Boston, United States
Anthony Philippakis is a Venture Partner at GV and a Chief Data Officer at Broad Institute. He was a Scientist at Broad Institute. Anthony attended Harvard Medical School, the University of Cambridge, and Yale University.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Anthony Philippakis invests in
Stages Anthony Philippakis invests in
Countries Anthony Philippakis invests in
Investment Focus
Industry
- Health Care 7 (30%)
- Biotechnology 7 (30%)
- Medical 4 (17%)
- Life Science 3 (13%)
- Therapeutics 3 (13%)
Stage
- Series A 5 (22%)
- Series B 5 (22%)
- Series C 4 (17%)
- Seed 2 (9%)
- Series D 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Iterative Health
|
Iterative Health is a healthcare technology and services company that focuses on accelerating clinical research to improve patient outcomes through innovative approaches. The company transforms gastrointestinal (GI) care by utilizing AI-driven clinical trials and diagnostics, significantly enhancing access to vital treatments. | $77M / Series C / Apr 30, 2026 | |
Beacon Biosignals
|
Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $11M / Series B / Apr 06, 2026 | |
Prudentia Sciences
|
Prudentia Sciences is a platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development. | $20M / Series A / Jan 07, 2026 | |
|
Beacon Biosignals
|
Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $86M / Series B / Nov 13, 2025 | |
Layer Health
|
Layer Health focuses on resolving the healthcare information problem by utilizing artificial intelligence to execute any clinical, administrative, or research work that involves chart review from unstructured data. | $29.5M / Series A / Mar 27, 2025 | |
|
Prudentia Sciences
|
Prudentia Sciences is a platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development. | $7M / Jan 09, 2025 | |
|
Prudentia Sciences
|
Prudentia Sciences is a platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development. | $7M / Seed / Jan 09, 2025 | |
Trace Neuroscience
|
Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses. | $101M / Series A / Nov 12, 2024 | |
|
Trace Neuroscience
|
Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses. | $101M / Series A / Nov 12, 2024 | |
Cardurion Pharmaceuticals
|
Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to addressunmet patient needs. | $260M / Series B / Jul 16, 2024 | |
| See all 23 investments → | |||
Co-Investors
About Google Ventures
Google Ventures invests in sectors including life sciences, consumer, enterprise, crypto, climate, and frontier technology. With Alphabet as its sole limited partner, Google Ventures focuses on long-term investments. Its operating partners assist startups in design, equity, diversity & inclusion, talent, and engineering and help them connectwith Google for technology and expertise. Founded in 2009 as Google Ventures, Google Ventures manages over $8 billion in assets with 400 active portfolio companies in North America and Europe. Some notable investments include Uber, Nest, Slack, GitLab, and One Medical. Google Ventures is based in the San Francisco Bay Area with offices in Cambridge, New York, and London.
Google Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andy Wheeler
Partner
|
|||
Anika Gupta
Principal
|
|||
|
Anthony Philippakis
Venture Partner
|
|||
Ben Robbins
General Partner
|
|||
Bethany Tsui
Principal and Investor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Anthony Philippakis invest in?
Anthony Philippakis invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Anthony Philippakis last invest?
The most recent investment recorded for Anthony Philippakis closed in Apr 2026. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
